Skip to main content

Advertisement

Log in

Methotrexate for rheumatoid arthritis patients who are on hemodialysis

  • Review Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Owen WF, Lew NL, Liu Y, Lowrie EG (1993) The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001–1006

    Article  PubMed  Google Scholar 

  2. Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK (2009) Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol 15(4):177–180

    Article  PubMed  Google Scholar 

  3. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21(7):1395–1403

    Google Scholar 

  4. Rosen G, Caparros B, Huros AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma. Cancer 49:1221–1230

    Article  PubMed  CAS  Google Scholar 

  5. Thierry FX, Vernier I, Dueymes JM, Roche H, Canal P, Meens F, Pourrat JP, Conte JJ (1989) Acute renal failure after high dose MTX therapy. Nephron 51:416–417

    Article  PubMed  CAS  Google Scholar 

  6. Hande KR, Balow JE, Drake JC (1977) Methotrexate and haemodalyisis. Ann Intern Med 87:495–496

    PubMed  CAS  Google Scholar 

  7. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci 332(3):156–158

    Article  PubMed  Google Scholar 

  8. Stoller RG, Kenneth RH, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 297:630–634

    Google Scholar 

  9. Feagan BG, Rochon J et al (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigations. N Engl J Med 332:292–297

    Article  PubMed  CAS  Google Scholar 

  10. Basile C, Montanaro A, Semeraro A (2002) Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transpl 17(3):530–531

    Google Scholar 

  11. Chess JA, Scholey G, Mikhail AI (2004) Neutropenia associated with the use of low-dose methotrexate in a peritoneal dialysis patient. Nephrol Dial Transpl 19(8):2158–2159

    Google Scholar 

  12. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272–276

    Article  PubMed  CAS  Google Scholar 

  13. Ellman MH, Ginsberg D (1990) Low dose methotrexate and severe neutropaenia in patients undergoing renal dialysis. Arthritis Rheum 33:1060–1061

    Article  PubMed  CAS  Google Scholar 

  14. Clatham WW, Morgan SL, Alarcon GS (2000) Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 43:1185–1186

    Article  Google Scholar 

  15. Chester KA, Baker M, Mayer A (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol 1(4):549–559

    Google Scholar 

  16. Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford) 45:357–359

    Article  CAS  Google Scholar 

  17. Gottenberg JE, Merle-Vincent F, Bentaberry F, Alanore Y, Berenbaum F, Fautrel B, Combe B, Durbarch A, Sibilia J, Dougados M, Mariette X (2003) Anti tumour necrosis factor a therapy in 15 patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48:2019–2024

    Article  PubMed  CAS  Google Scholar 

  18. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinouria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573

    Article  PubMed  Google Scholar 

  19. Hueber AJ, Tunc A, Schett G, Manger B (2007) Anti-tumour necrosis alpha therapy in patients with impaired renal function Ann. Rheum Dis 66:981–982

    Article  Google Scholar 

  20. Nestorov I (2005) Clinical pharmacokinetics of tumour necrosis factor antagonists. J Rheumatol 32(74):13–18

    Google Scholar 

  21. Singh R, Cuchacovich R, Huang W, Espinoza LR. (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29 (3):636–637

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Euthalia Roussou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Al-Hasani, H., Roussou, E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 31, 1545–1547 (2011). https://doi.org/10.1007/s00296-011-2041-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2041-5

Keywords

Navigation